On behalf of European Rare Disease community,
c4c submits a shared response to the FDA consultation
about a global clinical trials network in rare diseases

On May 29th this year, the FDA opened a consultation to obtain information and comments from patients, patient advocates, the scientific community, health professionals, other regulatory and health authorities in the global community, regulated industry, and the general public regarding practical steps and successful approaches to establish a global rare disease clinical trials network.   c4c convened representatives of the…

c4c – the WHY and the HOW

We are working to ensure children have the same rights as adults to access high quality, evidence-based medicines and health care services. We are fully committed to increasing high quality paediatric research.